Depression During and After the Perimenopause: Impact of Hormones, Genetics, and Environmental Determinants of Disease
- PMID: 30401549
- PMCID: PMC6226029
- DOI: 10.1016/j.ogc.2018.07.007
Depression During and After the Perimenopause: Impact of Hormones, Genetics, and Environmental Determinants of Disease
Abstract
Vulnerability to depression is increased across the menopause transition and in the early years after the final menstrual period. Clinicians should systematically screen women in this age group; if depressive symptoms or disorder are present, treatment of depression should be initiated. Potential treatments include antidepressants for moderate to severe symptoms, psychotherapy to target psychological and interpersonal factors, and hormone therapy for women with first-onset major depressive disorder or elevated depressive symptoms and at low risk for adverse effects. Behavioral interventions can improve physical activity and sleep patterns.
Keywords: Depression; Genetics; Hormones; Perimenopause; Psychosocial and health factors.
Copyright © 2018 Elsevier Inc. All rights reserved.
Figures
References
-
- Kessler RC, McGonagle KA, Zhao S et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Arch Gen Psychiatry 1994;51:8–19. - PubMed
-
- Freeman EW, Sammel MD, Liu L, Gracia CR, Nelson DB, Hollander L. Hormones and menopausal status as predictors of depression in women in transition to menopause. Arch Gen Psychiatry 2004;61:62–70. - PubMed
-
- American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5 ed 2013.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical